Soft tissue sarcoma (STS) · line 2 · Gemcitabine + docetaxel (soft tissue sarcoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-GEMCITABINE-DOCETAXEL-STS |
| ID | IND-STS-ADVANCED-2L-GEMDOC |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-SOFT-TISSUE-SARCOMA |
| Sources | SRC-SARC002-MAKI-2007 |
Used By
Algorithms
ALGO-STS-ADVANCED-2L- ALGO-STS-ADVANCED-2L